This paper is a review of the literature describing drug disposition in patients with end-stage renal disease (ESRD) during either intermittent peritoneal dialysis (IPD) or continuous ambulatory peritoneal dialysis (CAPD). The removal of drugs by peritoneal dialysis and drug absorption after intraperitoneal administration are examined. Detailed pharmacokinetic data extracted from the literature are presented in tabular form and are accompanied by specific dosage recommendations for dialyzed patients. Accepted literature values for parameters reflecting the effects of ESRD alone are also included. The construction of a rational dosage regimen with emphasis on the use of the aminoglycosides and the cephalosporins is described.
OreopoulosDo, RobsonM., FallerB.Continuous ambulatory peritoneal dialysis: A new era in the treatment of chronic renal failure.Clin Nephr1979; 11: 125–128.
KellerF., OffermannA., LodeH.Supplementary dose after hemodialysis.Nephron1982; 30: 220–227.
5.
BennettW.M., MutherR.S., ParkerR.A.Drug therapy in renal failure: Dosing guidelines for adults.Ann Intern Med1980; 93: (part I) 62-89 (Part II) 286–325.
6.
SomaniP., ShapiroR.S., StockardH.Unidirectional absorption of gentamicin fro m the peritoneum during continuous ambulatory peritoneal dialysis.Clin Pharmacol Ther1982; 32: 113–121.
7.
ZaskeD.E., CipolleR.J., StrateR.J.Gentamicin dosage requirements: Wide interpatient variation in 242 surgery patients with normal renal function.Surgery1980; 87: 164–169.
8.
DeRefentignyL., DumontL., LeLurierJ.Gentamicin: Use of a programmable calculator to determine dosages from pharmacokinetic data for individual patients.CMAJ1981; 124: 14591463.
9.
JuskoW.K., BaliahT., KimK.H.Pharmacokinetics of gentamicin during peritoneal dialysis in children.Kidney Int1976; 9: 430–438.
10.
MatzkeOr, SalemH., BockbraderH.The effect of peritoneal dialysis on the pharmacokinetics of amikacin.Proc Dial Transpl Forum1980; 10: 302304.
11.
RegeurL., ColdingH., JensenH.Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.Antimicrob Agents Chemother 197; 11: 214–218.
12.
MadhavanT., YaremchukK., LevinD.Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin.Antimicrob Agent Chemother1976; 10: 464–466.
13.
HamannS.R., OeltgenP.R., ShankW A.Evaluation of gentamicin pharmacokinetics during peritoneal dialysis.Ther Drug Monit1982; 4: 297300.
14.
GaryN.E.Peritoneal clearance and removal of gentamicin.I Infect Dis1971; 124: S96–S97 (suppl).
15.
SmithivasT., HyamsP., MatalonR.The use of gentamicin in peritoneal dialysis. I. Pharmacologic results.I Infect Dis1971; 124: 577–583.
16.
AtkinsR.C., MionC., DespauxE.Peritoneal transfer of kanamycin and its use in peritoneal dialysis.Kidney Int1973; 3: 391–396.
17.
GreenbergP.A., SanfordI.P.Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis.Ann Intern Med1967; 66: 465–478.
18.
RamosE., AdirI.A., ShenY.L.Pharmacokinetics of tobramycin in patients undergoing peritoneal dialysis.Kidney Int1979; 16: 896.
19.
IaffeG., MeyersB.R., HirschmanS.Z.Pharmacokinetics of tobramycin in patients with stable renal impainnent, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.Antimicrob Agents Chemother1974; 5: 611–616.
20.
MalacoffR.F., FinkelsteinF.O., AndrioleV.T.Effect of peritoneal dialysis on serum levels of tobramycin and clin darnycin.Antimicrob Agents Chemother1975; 8: 574–580.
21.
AhernM.I., FinkelsteinF.O., AndrioleV.T.Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.Antimicrob Agents Chemother1976; 10: 457–461.
22.
MeyersB.R., HirschmanS.Z.Pharmacokinetics of cefamandole in patients with renal failure.Antimicrob Agents Chemother1977; 11: 248–250.
23.
MadhavanT., YaremchukK., LevinN.Effects of renal failure and dialysis on cefazolin pharmacokinetics.Antimicrob Agents Chemother1975; 8: 63–66.
24.
LevisonM.E., LevisonS.P., RiesK.Pharmacology of cefazolin in patients with normal and abnormal renal function.I Infect Dis1973; 128: S354–S357 (Suppl).
25.
WiseR., WrightN., WillisP.I.Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.Antimicrob Agents Chemother1981; 19: 526–531.
26.
SchurigR., KampfD., SpieberW.Cefotaxim pharmacokinetics in peritoneal dialysis. In: GahlG.M., KesselM., NolphK.D., eds. Advances in Peritoneal Dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981: 96–98.
27.
LocalF.K., MunroA.I., KerrD.N.S.Pharmacokinetics of intravenous and intraperitoneal cefuroxime in patients undergoing peritoneal dialysis.Clin Nephrol1981; 16: 40–43.
28.
KosmidisI., StathakisC., AnyfantisA.Cefuroxime kinetics in renal insufficiency: Therapeutic results in various infections and pharmacokinetics including the effects of dialysis.Proc Roy Soc Med1977; 70: S139–S143 (Suppl).
29.
YamasakuF., TsuchidaR., UsudaY.A study of kinetics of cephalosporins in renal impainnent.I Postgrad Med1970; 46: S57–S59 (Suppl).
30.
GoodwinN.I., FriedmanE.A.The effects of renal impainnent, peritoneal dialysis and hemodialysis on serum sodium colistimethate levels.Ann Intern Med1968; 68: 984–994.
31.
CurtisI.R., EastwoodI.B.Colistin sulphomethate sodium administration in the presence of severe renal failure and during hemodialysis and peritoneal dialysis.BMI1968; 1: 484–485.
32.
ReinarzI.A., McIntoschD.A.Lincomycin excretion in patients with normal renal function, severe azotemia, and with hemodialysis and peritoneal dialysis.Antimicrob Agents Chemother1965; 5: 232–238.
33.
RuedyI.The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease.CMAJ1966; 94: 257–261.
34.
EastwoodI.B., CurtisI.R.Carbenicillin administration in patients with severe renal failure.BMI1968; 1: 486–487.
35.
KampfD., ShurigR., WeihermullerK.Effects of impaired renal function, hemodialysis and peritoneal dialysis on the pharmacokinetics of mezlocillin.Antimicrob Agents Chemother1980; 18: 81–87.
36.
ParryM.F., NeuH.C.Pharmacokinetics of ticarcillin in patients with abnormal renal function.I Infect Dis1976; 133: 46–49.
37.
SinglasE., ColinI.N., Rottembourgh. Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: Effect of peritonitis.Eur I Clin Pharmacol1982; 21: 409–415.
38.
NielsenH.E., SorensenI., HansenH.E.Peritoneal transport of vancomycin during peritoneal dialysis.Nephron1979; 24: 274–277.
39.
FishS.S., PancorboS., BerksethR.Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis.I Neurosurg1981; 54: 736–739.
40.
VaziriD., NessR.L., BartonC.H.Peritoneal dialysis clearance of cimetidine.Am I Gastoenterol1979; 71: 572576.
41.
PizzellaK.M., MooreM.C., SchultzR.W.Removal of cimetidine by peritoneal dialysis, hemodialysis and charcoal hemoperfusion.Ther Drug Monit1980; 2: 273–281.
42.
AckermanG.L., DohertyI.E., FlaniganW.I.Peritoneal dialysis and hemodialysis of tritiated digoxin.Ann Intern Med1967; 4: 718–723.
43.
BrownG.S., LohrT.O., MayorG.H.Peritoneal clearance of theophylline.Am I Kidney Dis1981; 1: 24–26.
44.
HallK., MeatherallB., KrahnI.Clearance of quinidine during peritoneal dialysis.Am Heart I1982; 104: 646–647.
45.
DettliL.Individualization of drug dosage in patients with renal disease.Med Clin N Amer1974; 58: 977–985.
46.
PancorboS., ComptyC.Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.Antimicrob Agents Chemother1981; 19: 605–607.
47.
PatonT.W., ManuelM.A., WalkerS.E.Tobramycin disposition in patients on continuous ambulatory peritoneal dialysis.Perit Dial Bull1982; 2: 179–181.
48.
BunkeC.M., AronoffG.R., BrierM.E.Pharmacokinetics of tobramycin in continuous ambulatory peritoneal dialysis.Clin Res1982; 30: 717A.
49.
PancorboS., ComptyC.Pharmacokinetics of cefamandole in patients undergoing continuous ambulatory peritoneal dialysis.Perit Dial Bull (in press).
50.
BunkeC.M., AronoffG.R., BrierM.E.Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis.Clin Pharmacol Ther1983; 33: 66–72.
51.
KellerE., IansenA., PelzK.Plasma levels of cefoperazon after intraperitoneal application.Clin Pharmacol Ther1983; 33: 235A.
RislerT., PetersU., PablickJ.Phannacokinetics of digoxin and digitoxin in patients on continuous ambulatory peritoneal dialysis. In: GahlG.M., KesselM., NolphK., eds. Advances in Peritoneal Dialysis. Proceedings of the Second International Conference on Peritoneal Dialysis, Amsterdam: Excerpta Medica, 1981: 88–89.
KayeD., WengerN., AgarwalB.Phannacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis.Antimicrob Agents Chemother.1978; 14: 318–321.
67.
LaGrecaG., BiasioliS., ChiaramonteS.Phannacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis.Int J Clin Pharmacol Ther Toxicol1982; 20: 92–94.
68.
WilliamsP., KhannaR., SimpsonH.Tobramycin blood levels of CAPD patients during peritonitis.Perit Dial Bull1982; 2: 48.
69.
PatonT.W., ManuelM.A., WalkerS.E.The disposition of cefazolin and tobramycin following intraperitoneal administration in patients on continuous ambulatory peritoneal dialysis.Perit Dial Bull (in press).
70.
DePaepeM., LameireN., BelpaireF.Peritoneal phannacokinetics of gentamicin in man.Clin Nephrol1983; 19: 107–109.
71.
CarneyS., ButcherR., DawbornJ.K.Minocycline excretion and distribution in relation to renal function in man.Clin Exp Phannacol Phys1974; 1: 299–308.
72.
RoseH.P., RothD.A., KochM.L.Serum tetracycline levels during peritoneal dialysis.Am J Med Sci1965; 250: 66–68.
